FIELD OF INVENTION
[001] The present disclosure relates to the field of cosmetics for the preparation of skin care formulations to inhibit the appearance of signs of skin aging.
BACKGROUND OF THE INVENTION
[002] Skin aging is a multifactorial phenomenon marked by decrease in synthesis of extracellular matrix (ECM) proteins like collagen and elastin, increase in protease activity leading to degradation of ECM and decrease in epidermal turnover. Skin aging manifests in the form of fine lines and wrinkles on the facial skin and other parts of the body. As skin ages, due to changes in the desquamation pattern, the epidermal barrier is disrupted which results in loss of natural moisturizing factors. Uncontrolled dehydration severely affects the ECM maintenance and continuity as a result of which skin becomes dry and thin. Literature survey reveals that active research is being carried out to increase the levels of collagen by boosting collagen synthesis, which can eventually decreases facial fine lines (Minayaar et al., J. Invest. Dermatol. Symp. Proc.; 2002, 7:51 -58; Ganceviciene et al., Dermatoendocrinol., 2012, 4(3):308-319). [003] US 8394395B2 describes the use of chrysin for treatment of fatty skin.
SUMMARY OF THE INVENTION
[004] In an aspect of the present disclosure, there is provided a composition
comprising: (a) chrysin; and (b) symglucan, wherein chrysin to symglucan w/w ratio in
said composition is in the range of 1:3.33-1:7.5.
[005] In an aspect of the present disclosure, there is provided a method of preparing a
composition comprising: (a) chrysin; and (b) symglucan, wherein chrysin to
symglucan w/w ratio in said composition is in the range of 1:3.33-1:7.5.
[006] In an aspect of the present disclosure, there is provided a method of inhibiting
appearance of skin aging, said method comprising: (i) obtaining a composition

comprising: (a) chrysin; and (b) symglucan, wherein chrysin to symglucan w/w ratio in said composition is in the range of 1:3.33-1:7.5; and (ii) contacting said composition with skin, wherein said method inhibits appearance of skin aging. [007] In an aspect of the present disclosure, there is provided a composition comprising: (a) chrysin; and (b) symglucan, wherein chrysin to symglucan w/w ratio in said composition is in the range of 1:3.33-1:7.5, for use in preparing topical formulations to inhibit appearance of skin aging.
[008] These and other features, aspects, and advantages of the present subject matter will be better understood with reference to the following description and appended claims. This summary is provided to introduce a selection of concepts in a simplified form. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS
[009] The following drawings form part of the present specification and are included
to further illustrate aspects of the present disclosure. The disclosure may be better
understood by reference to the drawings in combination with the detailed description
of the specific embodiments presented herein.
[0010] Figure 1 depicts the effect of chrysin at various concentrations on cell viability,
in accordance with an embodiment of the present disclosure.
[0011] Figure 2 depicts the effect of symglucan at various concentrations on cell
viability, in accordance with an embodiment of the present disclosure.
[0012] Figure 3 depicts the effect of oleonolic acid at various concentrations on cell
viability, in accordance with an embodiment of the present disclosure.
[0013] Figure 4 depicts the effect of Granzyme B acetate (GrB acetate) peptide acid at
various concentrations on cell viability, in accordance with an embodiment of the
present disclosure.

[0014] Figure 5 depicts the effect of royal jelly peptide acid at various concentrations
on cell viability, in accordance with an embodiment of the present disclosure.
[0015] Figure 6 depicts the effect of chrysin, oleanolic acid, and combination thereof
on involcurin levels in HaCaT cells, in accordance with an embodiment of the present
disclosure.
[0016] Figure 7 depicts the effect of chrysin, Granzyme B acetate peptide, and
combination thereof on involcurin levels in HaCaT cells, in accordance with an
embodiment of the present disclosure.
[0017] Figure 8 depicts the effect of chrysin, royal jelly, and combination thereof on
involcurin levels in HaCaT cells, in accordance with an embodiment of the present
disclosure.
[0018] Figure 9-10 depicts the effect of chrysin, symglucan, and combination thereof
at various concentrations on involcurin levels in HaCaT cells, in accordance with an
embodiment of the present disclosure.
DETAILED DESCRIPTION OF THE INVENTION
[0019] Those skilled in the art will be aware that the present disclosure is subject to variations and modifications other than those specifically described. It is to be understood that the present disclosure includes all such variations and modifications. The disclosure also includes all such steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any or more of such steps or features. Definitions
[0020] For convenience, before further description of the present disclosure, certain terms employed in the specification, and examples are collected here. These definitions should be read in the light of the remainder of the disclosure and understood as by a person of skill in the art. The terms used herein have the meanings

recognized and known to those of skill in the art, however, for convenience and
completeness, particular terms and their meanings are set forth below.
[0021] The articles “a”, “an” and “the” are used to refer to one or to more than one
(i.e., to at least one) of the grammatical object of the article.
[0022] The terms “comprise” and “comprising” are used in the inclusive, open sense,
meaning that additional elements may be included. It is not intended to be construed as
“consists of only”.
[0023] Throughout this specification, unless the context requires otherwise the word
“comprise”, and variations such as “comprises” and “comprising”, will be understood
to imply the inclusion of a stated element or step or group of element or steps but not
the exclusion of any other element or step or group of element or steps.
[0024] The term “including” is used to mean “including but not limited to”.
“Including” and “including but not limited to” are used interchangeably.
[0025] Unless defined otherwise, all technical and scientific terms used herein have
the same meaning as commonly understood by one of ordinary skill in the art to which
this disclosure belongs. Although any methods and materials similar or equivalent to
those described herein can be used in the practice or testing of the disclosure, the
preferred methods, and materials are now described. All publications mentioned herein
are incorporated herein by reference.
[0026] A composition comprising “synergistic activity” or a “synergistic composition”
is a combination of compounds which exhibits increased biological or functional
activity as a non-linear multiple of the biological or functional activity of the
individual compounds. In other words, the combined biological or functional activity
of two or more compounds being tested is significantly greater than the expected result
based on independent effects of the compounds when tested separately. Synergy may
be apparent only at some ranges or concentrations.
[0027] The present disclosure is not to be limited in scope by the specific
embodiments described herein, which are intended for the purposes of exemplification

only. Functionally-equivalent products, compositions, and methods are clearly within
the scope of the disclosure, as described herein.
[0028] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; and (b) symglucan, wherein chrysin to symglucan w/w ratio in
said composition is in the range of 1:3.33-1:7.5.
[0029] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; (b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin to symglucan w/w ratio in said
composition is in the range of 1:3.33-1:7.5.
[0030] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; and (b) symglucan, wherein chrysin weight percentage in said
composition is in the range of 0.0004-0.0006%, and symglucan weight percentage in
said composition is in the range of 0.002-0.003%.
[0031] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; (b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin weight percentage in said composition
is in the range of 0.0004-0.0006%, and symglucan weight percentage in said
composition is in the range of 0.002-0.003%.
[0032] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; and (b) symglucan, wherein chrysin to symglucan w/w ratio in
said composition is 1:5.
[0033] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; (b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin to symglucan w/w ratio in said
composition is 1:5.
[0034] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; and (b) symglucan, wherein chrysin weight percentage in said
composition is 0.0005%, and symglucan weight percentage in said composition is
0.0025%.

[0035] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin;(b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin weight percentage in said composition
is 0.0005%, and symglucan weight percentage in said composition is 0.0025%.
[0036] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein said composition is a liquid.
[0037] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein said composition is an aerosolized spray.
[0038] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein said composition is a gel.
[0039] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein said composition is a cream.
[0040] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein said suitable carriers, diluents, and excipients are cosmetic
grade not limited to fillers, stabilizers, humectants, preservatives, chelants, polymers,
and pigments.
[0041] In an embodiment of the present disclosure, there is provided a method of
inhibiting appearance of skin aging, said method comprising: (a) obtaining a
composition as described herein; and (b) contacting said composition with skin,
wherein said method inhibits appearance of skin aging.
[0042] In an embodiment of the present disclosure, there is provided a method of
inhibiting appearance of skin aging as described herein, wherein said composition
comprises: (a) chrysin; and (b) symglucan, wherein chrysin to symglucan w/w ratio in
said composition is in the range of 1:3.33-1:7.5.
[0043] In an embodiment of the present disclosure, there is provided a method of
inhibiting appearance of skin aging as described herein, wherein said composition
comprises: (a) chrysin; (b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin to symglucan w/w ratio in said
composition is in the range of 1:3.33-1:7.5.

[0044] In an embodiment of the present disclosure, there is provided a method of
inhibiting appearance of skin aging as described herein, wherein said composition
comprises: (a) chrysin; and (b) symglucan, wherein chrysin weight percentage in said
composition is in the range of 0.0004-0.0006%, and symglucan weight percentage in
said composition is in the range of 0.002-0.003%.
[0045] In an embodiment of the present disclosure, there is provided a method of
inhibiting appearance of skin aging as described herein, wherein said composition
comprises: (a) chrysin; (b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin weight percentage in said composition
is in the range of 0.0004-0.0006%, and symglucan weight percentage in said
composition is in the range of 0.002-0.003%.
[0046] In an embodiment of the present disclosure, there is provided a method of
inhibiting appearance of skin aging as described herein, wherein said composition
comprises: (a) chrysin; and (b) symglucan, wherein chrysin to symglucan w/w ratio in
said composition is 1:5.
[0047] In an embodiment of the present disclosure, there is provided a method of
inhibiting appearance of skin aging as described herein, wherein said composition
comprises: (a) chrysin; (b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin to symglucan w/w ratio in said
composition is 1:5.
[0048] In an embodiment of the present disclosure, there is provided a method of
inhibiting appearance of skin aging as described herein, wherein said composition
comprises: (a) chrysin; and (b) symglucan, wherein chrysin weight percentage in said
composition is 0.0005%, and symglucan weight percentage in said composition is
0.0025%.
[0049] In an embodiment of the present disclosure, there is provided a method of
inhibiting appearance of skin aging as described herein, wherein said composition
comprises: (a) chrysin; (b) symglucan; (c) at least one carrier, (d) at least one diluent,

and (e) at least one excipient, wherein chrysin weight percentage in said composition is 0.005%, and symglucan weight percentage in said composition is 0.0025%. [0050] In an embodiment of the present disclosure, there is provided a method of preparing a composition comprising: (a) chrysin and (b) symglucan, wherein chrysin to symglucan w/w ratio in said composition is in the range of 1:3.33-1:7.5, said method comprising: (a) obtaining a solution A of chrysin (b) obtaining a solution B of symglucan; and (c) contacting solution A, and solution B to obtain said composition. [0051] In an embodiment of the present disclosure, there is provided a method of preparing a composition comprising: (a) chrysin and (b) symglucan, wherein chrysin weight percentage in said composition is in the range of 0.0004-0.0006%, and symglucan weight percentage in said composition is in the range of 0.002-0.003%, said method comprising: (a) obtaining a solution A of chrysin (b) obtaining a solution B of symglucan; and (c) contacting solution A, and solution B to obtain said composition.
[0052] In an embodiment of the present disclosure, there is provided a method of preparing a composition comprising: (a) chrysin (b) symglucan; (c) at least one carrier, (d) at aleast one diluent, and (e) at least one excipient, wherein chrysin to symglucan w/w ratio in said composition is in the range of 1:3.33-1:7.5, said method comprising: (a) obtaining a solution A of chrysin (b) obtaining a solution B of symglucan; (c) obtaining a solution C of at least one carrier, diluent, and excipient; and (d) contacting solution A, solution B, and solution C to obtain said composition. [0053] In an embodiment of the present disclosure, there is provided a method of preparing a composition comprising: (a) chrysin (b) symglucan; (c) at least one carrier, (d) at aleast one diluent, wherein chrysin weight percentage in said composition is in the range of 0.0004-0.0006%, and symglucan weight percentage in said composition is in the range of 0.002-0.003%, said method comprising: (a) obtaining a solution A of chrysin (b) obtaining a solution B of symglucan; (c) obtaining a solution C of at least one carrier, diluent, and excipient; and (d) contacting solution A, solution B, and solution C to obtain said composition.

[0054] In an embodiment of the present disclosure, there is provided a method of preparing a composition comprising: (a) chrysin and (b) symglucan, wherein chrysin to symglucan w/w ratio in said composition is 1:5, said method comprising: (a) obtaining a solution A of chrysin (b) obtaining a solution B of symglucan; and (c) contacting solution A, and solution B to obtain said composition.
[0055] In an embodiment of the present disclosure, there is provided a method of preparing a composition comprising: (a) chrysin and (b) symglucan, wherein chrysin weight percentage in said composition is 0.0005%, and symglucan weight percentage in said composition is 0.0025%, said method comprising: (a) obtaining a solution A of chrysin (b) obtaining a solution B of symglucan; and (c) contacting solution A, and solution B to obtain said composition.
[0056] In an embodiment of the present disclosure, there is provided a method of preparing a composition comprising: (a) chrysin (b) symglucan; (c) at least one diluent, (d) at least one carrier, and (e) at least one excipient, wherein chrysin to symglucan w/w ratio in said composition is 1:5, said method comprising: (a) obtaining a solution A of chrysin (b) obtaining a solution B of symglucan; (c) obtaining a solution C of at least one carrier, diluent, and excipient; and (d) contacting solution A, solution B, and solution C to obtain said composition.
[0057] In an embodiment of the present disclosure, there is provided a method of preparing a composition comprising: (a) chrysin (b) symglucan; and (c) suitable carriers, diluents, and excipients, wherein chrysin weight percentage in said composition is 0.0005%, and symglucan weight percentage in said composition is 0.0025%, said method comprising: (a) obtaining a solution A of chrysin (b) obtaining a solution B of symglucan; (c) obtaining a solution C of suitable carriers, diluents, and excipients; and (d) contacting solution A, solution B, and solution C to obtain said composition.
[0058] In an embodiment of the present disclosure, there is provided a composition comprising: (a) chrysin; and (b) symglucan, wherein chrysin to symglucan w/w ratio in

said composition is in the range of 1:3.33-1:7.5, for use in preparing topical
formulations to inhibit appearance of skin aging.
[0059] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; (b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin to symglucan w/w ratio in said
composition is in the range of 1:3.33-1:7.5, for use in preparing topical formulations to
inhibit appearance of skin aging.
[0060] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; (b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin weight percentage in said composition
is in the range of 0.0004-0.0006%, and symglucan weight percentage in said
composition is in the range of 0.002-0.003%, for use in preparing topical formulations
to inhibit appearance of skin aging.
[0061] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin;(b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin to symglucan w/w ratio in said
composition is 1:5, for use in preparing topical formulations to inhibit appearance of
skin aging.
[0062] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; (b) symglucan; (c) at least one carrier, (d) at least one diluent,
and (e) at least one excipient, wherein chrysin weight percentage in said composition
is 0.0005%, and symglucan weight percentage in said composition is 0.0025%, for use
in preparing topical formulations to inhibit appearance of skin aging.
[0063] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; and (b) symglucan;, wherein chrysin to symglucan w/w ratio
in said composition is 1:5, for use in preparing topical formulations to inhibit
appearance of skin aging.
[0064] In an embodiment of the present disclosure, there is provided a composition
comprising: (a) chrysin; and (b) symglucan; wherein chrysin weight percentage in said

composition is 0.0005%, and symglucan weight percentage in said composition is 0.0025%, for use in preparing topical formulations to inhibit appearance of skin aging. [0065] Although the subject matter has been described in considerable detail with reference to certain preferred embodiments thereof, other embodiments are possible.
EXAMPLES
[0066] The disclosure will now be illustrated with working examples, which is intended to illustrate the working of disclosure and not intended to take restrictively to imply any limitations on the scope of the present disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods, devices and materials are described herein. It is to be understood that this disclosure is not limited to particular methods, and experimental conditions described, as such methods and conditions may vary.
Example 1
Materials and methods
[0067] Chrysin was purchased from Sigma. 1% stock solution of Symglucan was obtained from Symrise, India. Granzyme B acetate peptide (amino acid sequence IEPD) was procured from USV Ltd, and royal jelly was bought from Anaspec Inc. [0068] Determination of involcurin levels: HaCaT cells (NCCS pune) were seeded in 12- well plates (Costar) in MC154 medium (Invitrogen). The culture was incubated in 5% CO2 incubator. Experimentation procedure consists of 8 days. The cells were seeded on day 1, actives were treated on Day 2 and Day 5. Cells were lysed and harvested in RIPA buffer (Invitrogen) on Day 8. Cell lysates was subjected to freeze-thaw cycle followed by sonication. Protein estimation was carried out with Nanoorange protein quantification kit (Invitrogen) as per the manufacturer’s protocol. Involucrin ELISA was performed as per manufacturer’s protocol (USCN Lifesciences)

to estimate secreted Involucrin. Involcurin is bio marker for measure anti-aging effects in skin (Kim et al., J Microbiol Biotechnol. 2015, ;25(10):1589-98). [0069] The various compositions were prepared by dissolving requisite quantities of extract ingredients in DMSO to prepare the stock solutions.
Example 2
Results
[0070] In order to ascertain the effect of chrysin on cell viability, HaCaT cells were
treated with various concentrations of chrysin ranging from 0.00025-0.002%. As seen
in Figure 1, while chrysin concentrations ranging from 0.00025-0.0015% as tested do
not affect cell viability, at higher concentrations ( 0.02% as tested), show a decrease in
cell viability by 34% as compared to cells treated with the vehicle control (Cells
treated with DMSO, the solvent used for diluting the active ingredient, viz chrysin, and
symglucan). .
[0071] Similarly, Figure 2 depicts the effect of symglucan at various concentrations
ranging from 0.0625-5% on HaCaT cell viability. It can be inferred that for all the
various concentrations tested, symglucan is not toxic to the cells.
[0072] Figure 3 depicts the effect of oleonolic acid at concentrations ranging from
0.0156-0.25% on fibroblast cell viability. For concentrations tested ranging from
0.0156-0.25% (0.25, 0.125, 0.0625, 0.0313, and 0.0156%), is not toxic to cells.
[0073] Figure 4 depicts the effect of Granzyme B acetate peptide at various
concentrations on HaCaT cells viability. As seen from Figure 4, Granzyme B acetate
peptide at as tested concentrations of 0.000078, and 0.000039% do not exhibit toxicity
as cell viability is similar/greater than that of the vehicle control. In contrast, at higher
concentrations, at 0.000156% concentration cell viability is 90%, at 0.0003125%
concentration cell viability is 76%, while at concentrations of 0.000625 or 0.00125%,
the cell viability is less than 60%.
[0074] Figure 5 depicts the effect of royal jelly peptide at concentrations ranging from
0.000039-0.00125% on cell viability. For concentrations tested ranging from
0.000039-0.00125%, is not toxic to cells

[0075] Based on the cell viability results as discussed above, particular individual concentrations of chrysin, royal jelly peptide, oleanolic acid, Granzyme B acetate peptide symglucan, were selected to study the effect of various combinations on involucrin protein expression. Figure 6 depicts the effect of a combination of chrysin (C), and oleanolic acid (O) on involucrin protein expression in HaCaT cells. It can be seen that chrysin alone at a concentration of 0.005% (C0.005%) enhances involucrin protein expression by about 4% compared to vehicle control. Oleanolic acid at a concentration of 0.0001% (O0.0001%) decreases involucrin protein expression by about12% compared to control. The combination in contrast, having chrysin concentration of 0.0005% and oleanolic acid having concentration of 0.0001% (C+O 0.0005%+0.0001%), further decrease involucrin protein expression 17%, suggesting that the combination in fact antagonizes involucrin expression when compared to the effect of chrysion, or oleanolic acid alone.
[0076] Figure 7 depicts the effect of chrysin and Granzyme B acetate peptide on involucrin protein expression. Chrysin at a concentration of 0.005% (C0.005%) enhances collagen secretion by 11% compared to control. 0.00015% Granzyme B acetate peptide (G0.00015%) enhances involucrin protein expression by 3% by 24%. However, the combination of chrysin at concentration of 0.005% and Granzyme B acetate peptide at concentration of 0.00015% (A+G 0.005%+0.00015%) provided for an enhancement in protein expression similar to that achieved with 0.00015% of Granzyme B acetate peptide.
[0077] Figure 8 depicts the effect of a combination of chrysin and royal jelly peptide oninvolucrin protein expression in HaCaT cells. Chrysin alone at a concentration of 0.005% (C0.005%) enhances involcurin protein expression compared to control by about 4%, and royal jelly at a concentration of 0.0003% (R0.0003%) by 31%, The combination of chrysin a at concentration of 0.005% and royal jelly acid at a concentration of 0.0003% (C+R 0.0005%+0.0003%) depresses expression by 20%. [0078] Figure 9 depicts the effect of a combination of chrysin (C), and symglucan (S) on involucrin protein expression in HaCaT cells. It can be seen that chrysin alone at a

concentration of 0.005% (C0.005%) enhances involucrin protein expression by about 10% compared to vehicle control. Symglucan at a concentration of 0.0025% (S0.0025%) decreases involucrin protein expression by about 3% compared to control. The combination in contrast, having chrysin concentration of 0.0005% and symglucan having concentration of 0.0025% (C+S 0.0005%+0.0025%) (w/w ratio of 1:5), unexpectedly and surprisingly synergistically enhances involucrin protein expression by about 29%, which is more than the expected additive effect. In order to ascertain whether the synergism as observed is limited to the particular concentrations of chrysin and symglucan, other concentrations were also tested. As depicted in figure 10, the combination chrysin at 0.0005%, and symglucan at 0.005% demonstrates a protein expression of 10%. However symglucan (S0.005%) at a concentration of 0.005% enhances protein expression by 23%. Thus the combination of combination of chrysin and symglucan at a w/w ratio of 1:10 exhibits no synergy in protein expression enhancement.
[0079] Overall, these data show that a combination of chrysin and symglucan at a particular w/w ratio and concentrations, which is not toxic to cells surprisingly exhibits synergism in enhancing involcurin expression in HaCaT cells, which is an established biomarker for younger looking skin.. Further, arriving at this combination is not a matter of routine experimentation/trial and error on part of a person skilled in the art as evidenced by supporting data to show that a combination of chrysin with royal jelly, or oleanolic acid, or Granzyme B acetate peptide in combination do not show any enhanced expression. These findings can find application in synthesis of formulations for topical application to skin in order to enhance its visual appeal by inhibiting appearance of wrinkles and fine lines.

I/We Cl ai m :
1. A composition comprising:
a. chrysin; and
b. symglucan,
wherein chrysin to symglucan w/w ratio in said composition is in the range of 1:3.33-1:7.5.
2. The composition as claimed in claim 1, wherein chrysin weight percentage in said composition is in the range of 0.0004-0.0006%, and symglucan weight percentage in said composition is in the range of 0.002-0.003%.
3. The composition as claimed in claim 1, wherein chrysin to symglucan w/w ratio in said composition is 1:5.
4. The composition as claimed in claim 3, wherein chrysin weight percentage in said composition is 0.0005%, and symglucan weight percentage in said composition is 0.0025%.
5. The composition as claimed in any of the claims 1-4, further comprising (a) at least one carrier, (b) at least one diluent, and (c) at least one excipient.
6. A method of preparing a composition as claimed in any of the claims 1-5.
7. A method of inhibiting appearance of skin aging, said method comprising:
a. obtaining a composition as claimed in any of the claims 1-5; and
b. contacting said composition with skin,
wherein said method inhibits appearance of skin aging.

8. A composition as claimed in any of the claims 1-5 for use in preparing topical
formulations to inhibiting appearance of skin aging.